Literature DB >> 22740935

Effects of 4-1BB signaling on the biological function of murine dendritic cells.

Youlin Kuang1, Xiaodong Weng, Xiuheng Liu, Hengchen Zhu, Zhiyuan Chen, Hui Chen.   

Abstract

4-1BB signaling has profound effects on the T cell-induced cell immune response, but its biological function in dendritic cells (DCs) has remained largely uncharacterized. In this study, we investigated the function of 4-1BB in murine DCs with an agonistic mAb to 4-1BB. Interleukin (IL)-6 and IL-12 production was assessed by an enzyme-linked immunosorbent assay (ELISA). Co-stimulatory molecules (CD80 and CD86) in DCs were analyzed by flow cytometry. The results showed that 4-1BB was strongly expressed in DCs during the maturation process. Triggering 4-1BB increased the secretion of IL-6 and IL-12 and the upregulation of co-stimulatory molecules (CD80 and CD86) from DCs, indicating that agonistic mAb to 4-1BB directly improves the activation of DCs. Moreover, triggering 4-1BB induced a higher survival rate of DCs compared to that of hamster IgG isotype control, due to the upregulated expression of Bcl-2 and Bcl-xL. To further assess the role of 4-1BB on DCs stimulating T-cell proliferation, allogeneic mixed lymphocyte reactions were analyzed. The agonistic anti-4-1BB mAb induced a higher T-cell proliferation. These results suggest that 4-1BB affects the duration, DC-T interaction and immunogenicity of DCs.

Entities:  

Year:  2011        PMID: 22740935      PMCID: PMC3362585          DOI: 10.3892/ol.2011.506

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  16 in total

Review 1.  Role of T cell costimulation in anti-viral immunity.

Authors:  Edward M Bertram; Wojciech Dawicki; Tania H Watts
Journal:  Semin Immunol       Date:  2004-06       Impact factor: 11.130

2.  4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines.

Authors:  Chie Kudo-Saito; James W Hodge; Heesun Kwak; Seunghee Kim-Schulze; Jeffrey Schlom; Howard L Kaufman
Journal:  Vaccine       Date:  2006-03-31       Impact factor: 3.641

3.  Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors.

Authors:  I Melero; W W Shuford; S A Newby; A Aruffo; J A Ledbetter; K E Hellström; R S Mittler; L Chen
Journal:  Nat Med       Date:  1997-06       Impact factor: 53.440

4.  B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

Authors:  Zhao-Yang Lu; Maud Condomines; Karin Tarte; Laure Nadal; Marie Claude Delteil; Jean François Rossi; Christophe Ferrand; Bernard Klein
Journal:  Exp Hematol       Date:  2007-03       Impact factor: 3.084

5.  Soluble PD-1 facilitates 4-1BBL-triggered antitumor immunity against murine H22 hepatocarcinoma in vivo.

Authors:  Han Xiao; Bo Huang; Ye Yuan; Dong Li; Ling-Fei Han; Yi Liu; Wei Gong; Feng-Hua Wu; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Clin Cancer Res       Date:  2007-02-26       Impact factor: 12.531

6.  Differential expression and costimulatory effect of 4-1BB (CD137) and CD28 molecules on cytokine-induced murine CD8(+) Tc1 and Tc2 cells.

Authors:  D S Vinay; B S Kwon
Journal:  Cell Immunol       Date:  1999-02-25       Impact factor: 4.868

7.  Evaluating the cellular targets of anti-4-1BB agonist antibody during immunotherapy of a pre-established tumor in mice.

Authors:  Gloria H Y Lin; Yuanqing Liu; Thanuja Ambagala; Byoung S Kwon; Pamela S Ohashi; Tania H Watts
Journal:  PLoS One       Date:  2010-06-08       Impact factor: 3.240

8.  4-1BB co-stimulation enhances human CD8(+) T cell priming by augmenting the proliferation and survival of effector CD8(+) T cells.

Authors:  Diego Laderach; Mojgan Movassagh; Anthony Johnson; Robert S Mittler; Anne Galy
Journal:  Int Immunol       Date:  2002-10       Impact factor: 4.823

9.  Bcl-2 controls dendritic cell longevity in vivo.

Authors:  Adam Nopora; Thomas Brocker
Journal:  J Immunol       Date:  2002-09-15       Impact factor: 5.422

Review 10.  The use of dendritic cells in cancer immunotherapy.

Authors:  Alessio Nencioni; Frank Grünebach; Susanne M Schmidt; Martin R Müller; Davide Boy; Franco Patrone; Alberto Ballestrero; Peter Brossart
Journal:  Crit Rev Oncol Hematol       Date:  2007-12-04       Impact factor: 6.312

View more
  7 in total

1.  CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer.

Authors:  Raghvendra M Srivastava; Sumita Trivedi; Fernando Concha-Benavente; Sandra P Gibson; Carly Reeder; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2016-08-05       Impact factor: 12.531

2.  Dendritic cell maturation and survival are differentially regulated by TNFR1 and TNFR2.

Authors:  Anja Krippner-Heidenreich; Catharien M U Hilkens; Nicola J Maney; Gary Reynolds
Journal:  J Immunol       Date:  2014-10-06       Impact factor: 5.422

Review 3.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

Review 4.  The Roles of CD137 Signaling in Atherosclerosis.

Authors:  In-Hyuk Jung; Goo Taeg Oh
Journal:  Korean Circ J       Date:  2016-10-20       Impact factor: 3.243

5.  4-1BB Signaling in Conventional T Cells Drives IL-2 Production That Overcomes CD4+CD25+FoxP3+ T Regulatory Cell Suppression.

Authors:  Hampartsoum B Barsoumian; Esma S Yolcu; Haval Shirwan
Journal:  PLoS One       Date:  2016-04-06       Impact factor: 3.240

Review 6.  4-1BB agonism: adding the accelerator to cancer immunotherapy.

Authors:  Cariad Chester; Siddhant Ambulkar; Holbrook E Kohrt
Journal:  Cancer Immunol Immunother       Date:  2016-03-31       Impact factor: 6.968

7.  Dendritic cell maturation in the corneal epithelium with onset of type 2 diabetes is associated with tumor necrosis factor receptor superfamily member 9.

Authors:  Neil S Lagali; Reza A Badian; Xu Liu; Tobias R Feldreich; Johan Ärnlöv; Tor Paaske Utheim; Lars B Dahlin; Olov Rolandsson
Journal:  Sci Rep       Date:  2018-09-24       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.